PROGRAM
TARGET ID & VALIDATION
DRUG
DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PARTNER¹
PROGRAM
TARGET ID & VALIDATION
DRUG
DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PARTNER¹
Small molecule
PROGRAM
TARGET ID & VALIDATION
DRUG
DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PARTNER¹
Small molecule Oricula Therapeutics logo
DB-XX1 Balance Dysfunction
PROGRAM
TARGET ID & VALIDATION
DRUG
DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PARTNER¹
Gene Therapy Regeneron logo
DB-XX2 Monogenic Hearing Loss: Gene 1
PROGRAM
TARGET ID & VALIDATION
DRUG
DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PARTNER¹
Gene Therapy Regeneron logo
DB-XX3 Monogenic Hearing Loss: Gene 2
PROGRAM
TARGET ID & VALIDATION
DRUG
DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PARTNER¹
Gene Therapy Regeneron logo
DB-XX4 Monogenic Hearing Loss: Gene 3
PROGRAM
TARGET ID & VALIDATION
DRUG
DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PARTNER¹
Gene Therapy Regeneron logo
DB-XX5 Tinnitus; Auditory Neuropathy
PROGRAM
TARGET ID & VALIDATION
DRUG
DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PARTNER¹
Biologic Regeneron logo
Novel target ID Noise, Age,
Tinnitus, Balance
PROGRAM
TARGET ID & VALIDATION
DRUG
DISCOVERY
IND ENABLING STUDIES (GLP)
PHASE I
PARTNER¹
Regeneron logo

1. Decibel retains worldwide development and commercial rights for all programs
2. Regeneron co-funds the development of collaboration programs and receives tiered royalties based on net sales.